| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 245.090 | 283.435 | 319.440 | 335.723 | 341.122 | 368.469 | 354.431 | 462.379 | 623.671 | 609.826 |
| Total Income - EUR | 248.414 | 299.825 | 320.792 | 335.829 | 341.148 | 368.777 | 355.606 | 470.946 | 623.843 | 617.914 |
| Total Expenses - EUR | 258.718 | 292.471 | 303.890 | 315.622 | 322.061 | 353.474 | 336.095 | 436.227 | 598.574 | 579.388 |
| Gross Profit/Loss - EUR | -10.304 | 7.354 | 16.901 | 20.208 | 19.087 | 15.303 | 19.511 | 34.718 | 25.269 | 38.526 |
| Net Profit/Loss - EUR | -10.304 | 7.354 | 11.844 | 16.849 | 15.679 | 12.251 | 16.275 | 30.621 | 20.390 | 33.099 |
| Employees | 50 | 49 | 49 | 46 | 46 | 46 | 34 | 36 | 40 | 38 |
Check the financial reports for the company - Apoterm Sa
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 100.419 | 96.044 | 91.357 | 91.547 | 89.210 | 85.815 | 91.174 | 108.082 | 107.488 | 164.284 |
| Current Assets | 104.514 | 107.162 | 85.083 | 78.066 | 73.856 | 87.763 | 90.473 | 108.611 | 135.945 | 155.362 |
| Inventories | 581 | 422 | 82 | 80 | 342 | 148 | 23 | 126 | 125 | 23 |
| Receivables | 46.798 | 55.443 | 45.358 | 16.371 | 15.928 | 48.006 | 22.806 | 34.430 | 78.262 | 72.604 |
| Cash | 17.746 | 12.311 | 1.316 | 23.992 | 20.691 | 3.413 | 32.251 | 38.553 | 22.164 | 47.537 |
| Shareholders Funds | 178.026 | 92.415 | 99.930 | 114.946 | 128.399 | 138.216 | 151.426 | 182.516 | 202.353 | 234.321 |
| Social Capital | 39.650 | 39.245 | 38.581 | 37.873 | 37.140 | 36.436 | 35.628 | 35.738 | 35.630 | 35.431 |
| Debts | 26.907 | 110.791 | 76.510 | 54.668 | 34.668 | 35.362 | 30.533 | 34.397 | 41.612 | 45.752 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40.134 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8130 - 8130" | |||||||||
| CAEN Financial Year |
8130
|
|||||||||
Comments - Apoterm Sa